Patents by Inventor Michael S. Urdea

Michael S. Urdea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PATHOGEN TESTING SYSTEMS AND METHODS OF USE THEREOF
    Publication number: 20240061002
    Abstract: Provided herein are mobile systems for sample processing. In some aspects, provided herein are mobile systems for sample processing and methods of use thereof for detection of pathogens in biological samples.
    Type: Application
    Filed: January 5, 2022
    Publication date: February 22, 2024
    Inventors: Peter James Dailey, Richard McGregor Thayer, Laura Terese Mazzola, Paul Scott Eastman, Michael S. Urdea, Jesse Charles Darley, Ryan Lee Anton, Katherine Gail Mason, Sara Willoughby Berg-Love, Justin Daniel Chan, Russell Prince, Douglas Paul Barnes, Evan Alex Bunke, Jacob Emory Schepp, Douglas E. Seals, Alexandra A. Surasky-Ysasi, Angie Purvis, Christina Newman, Dawn Dudley, David O'Connor, Thomas Friedrich, Steven Carbone, Madalyn Gill, Brianna Mullins, Jay Warrick, Patrick McMinn, Dave Beebe, Ryan Shogren, Mitch Geiger, Franklin Zhong, Duane S. Juang, Terry D. Juang
  • Systems and Methods for Developing Diagnostic Tests Based on Biomarker Information from Legacy Clinical Sample Sets
    Publication number: 20180267053
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 or less of a legacy clinical sample.
    Type: Application
    Filed: March 12, 2018
    Publication date: September 20, 2018
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Systems and Methods for Developing Diagnostic Tests Based on Biomarker Information from Legacy Clinical Sample Sets
    Publication number: 20160139139
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L. or less of a legacy clinical sample.
    Type: Application
    Filed: January 27, 2016
    Publication date: May 19, 2016
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Diabetes-related biomarkers and methods of use thereof
    Patent number: 9034585
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 19, 2015
    Assignee: Health Diagnostic Laboratory, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Systems and Methods for Developing Diagnostic Tests Based on Biomarker Information from Legacy Clinical Sample Sets
    Publication number: 20130267442
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L or less of a legacy clinical sample.
    Type: Application
    Filed: January 21, 2013
    Publication date: October 10, 2013
    Applicant: TETHYS BIOSCIENCE, INC.
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Diabetes-related biomarkers and methods of use thereof
    Patent number: 8409816
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: April 2, 2013
    Assignee: Tethys Bioscience, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
    Patent number: 8357497
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L or less of a legacy clinical sample.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: January 22, 2013
    Assignee: Tethys Bioscience, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Methods for Use with Nanoreactors
    Publication number: 20120322065
    Abstract: The invention relates to methods of using nanoreactor technology for sample analysis in microfluidic systems.
    Type: Application
    Filed: May 22, 2012
    Publication date: December 20, 2012
    Inventors: Michael S. Urdea, Theodore M. Tarasow, Edward J. Moler
  • SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM LEGACY CLINICAL SAMPLE SETS
    Publication number: 20120289434
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L or less of a legacy clinical sample.
    Type: Application
    Filed: July 30, 2012
    Publication date: November 15, 2012
    Applicant: TETHYS BIOSCIENCE, INC.
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
    Patent number: 8232065
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L or less of a legacy clinical sample.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: July 31, 2012
    Assignee: Tethys Bioscience, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna
  • DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF
    Publication number: 20120179484
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Application
    Filed: October 5, 2011
    Publication date: July 12, 2012
    Applicant: TETHYS BIOSCIENCE, INC.
    Inventors: MICHAEL S. URDEA, Michael P. McKenna, Patrick A. Arensdorf
  • Diabetes-related biomarkers and methods of use thereof
    Patent number: 8119358
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: February 21, 2012
    Assignee: Tethys Bioscience, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Multiplex protein fractionation
    Patent number: 8097425
    Abstract: The invention provides methods, compositions, and kits for multiplex fractionation of proteins in a sample. Protein-binding molecules, such as small epitope antibodies or small epitope aptamers, are used for multiplex fractionation of proteins in a protein containing sample. Detection of fractionated proteins may be used for characterization of proteins in a sample in applications such as expression profiling, identification and/or quantification of proteins in a sample, and identification or detection of biomarkers.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: January 17, 2012
    Assignee: Tethys Bioscience, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Scott Eastman
  • SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM LEGACY CLINICAL SAMPLE SETS
    Publication number: 20110098187
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L or less of a legacy clinical sample.
    Type: Application
    Filed: May 8, 2007
    Publication date: April 28, 2011
    Applicant: TETHYS BIOSCIENCE, INC.
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Diabetes-related biomarkers and methods of use thereof
    Patent number: 7723050
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: May 25, 2010
    Assignee: Tethys Bioscience, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • METHODS FOR USE WITH NANOREACTORS
    Publication number: 20100075436
    Abstract: The invention relates to methods of using nanoreactor technology for sample analysis in microfluidic systems.
    Type: Application
    Filed: May 6, 2009
    Publication date: March 25, 2010
    Inventors: Michael S. URDEA, Theodore M. TARASOW, Edward J. MOLER
  • DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF
    Publication number: 20090271124
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Application
    Filed: July 10, 2009
    Publication date: October 29, 2009
    Applicant: TETHYS BIOSCIENCE, INC.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Diabetes-related biomarkers and methods of use thereof
    Publication number: 20090012716
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Application
    Filed: April 18, 2008
    Publication date: January 8, 2009
    Applicant: Tethys Bioscience, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Binding reagents that contain small epitope binding molecules
    Publication number: 20080280778
    Abstract: The invention provides binding reagents that contain a plurality of linked small epitope binding molecules that each recognizes a small epitope, such as small epitope antibodies. The combination of small epitope binding molecules in a binding reagent specifically recognizes and binds to a molecule of interest. The binding reagents may be used for such purposes as detection, quantification, identification, and purification of molecules of interest.
    Type: Application
    Filed: May 2, 2008
    Publication date: November 13, 2008
    Inventor: Michael S. Urdea
  • Methods for reducing complexity of a sample using small epitope antibodies
    Publication number: 20080241934
    Abstract: The present invention relates generally to methods for reducing the complexity of a sample. More specifically, the present invention relates to proteomics, the measurement of the protein levels in biological samples, and analysis of proteins in a sample using antibodies that recognize small epitopes.
    Type: Application
    Filed: August 7, 2007
    Publication date: October 2, 2008
    Inventors: Michael S. Urdea, Gregory M. Landes, Gregory T. Went